Product Details – Cagrilintide

Cagrilintide is a synthetic peptide analog of amylin, a peptide hormone associated with metabolic signaling systems. It is structurally modified to enhance stability in controlled laboratory environments, allowing for consistent investigation in experimental settings.

In research applications, cagrilintide is utilized to study peptide-receptor interactions and signaling pathways associated with amylin receptor systems. Its structure supports detailed examination of ligand binding behavior and receptor-mediated intracellular processes.

This compound is supplied strictly for laboratory research purposes and is not intended for consumption, medical, or diagnostic use.

Mechanism of Action

At the molecular level, cagrilintide is studied for its interaction with amylin receptors (AMY receptors), which are complexes involving calcitonin receptors and receptor activity-modifying proteins (RAMPs). Upon binding, the receptor-ligand interaction initiates intracellular signaling cascades, including cyclic adenosine monophosphate (cAMP) pathway activation.

These signaling processes are analyzed in vitro to evaluate receptor activation, ligand affinity, and downstream intracellular communication. Researchers examine how receptor engagement influences signaling networks associated with peptide-mediated regulatory pathways.

Additionally, cagrilintide is investigated for its role in modulating pathways associated with gastric signaling, neuroendocrine communication, and metabolic-related receptor activity at the molecular level under controlled experimental conditions.

Chemical Properties of Cagrilintide

Research Applications

Receptor Binding Studies

Cagrilintide is utilized in experimental systems to examine ligand interaction with amylin receptor complexes. Researchers analyze receptor activation, binding affinity, and signal initiation at the molecular level.

Intracellular Signaling Analysis

This compound is applied in studies investigating GPCR-related signaling pathways, including cAMP-mediated intracellular communication and downstream regulatory mechanisms.

Peptide Signaling Research

Cagrilintide supports investigations into peptide-mediated signaling networks, including those associated with neuroendocrine and receptor-modulating pathways under controlled laboratory conditions.

Why Choose BehemothLabz to Buy Cagrilintide for Research

BehemothLabz supplies research-grade Cagrilintide produced under controlled laboratory conditions with strict quality assurance protocols in place. Each batch undergoes detailed analytical verification to ensure consistency in molecular composition and purity.

In addition, comprehensive documentation, including laboratory testing reports and sourcing transparency, supports reproducibility across experimental applications. BehemothLabz maintains a compliance-focused approach, ensuring that all compounds are supplied exclusively for laboratory-based investigation and analytical research.

Disclaimer

Cagrilintide is intended strictly for laboratory research and analytical purposes only. It is not designed for diagnostic procedures, therapeutic applications, or any form of in vivo study.

All references to biochemical pathways, receptor interactions, and enzymatic processes are provided solely within a research context. This compound must be handled only by qualified professionals within controlled laboratory environments, in accordance with applicable regulations and safety standards.

Any use outside of these defined research conditions is strictly prohibited.

References

• Lau, D. C. W., Erichsen, L., Francisco, A. M., Satylganova, A., le Roux, C. W., McGowan, B., Pedersen, S. D., Pietiläinen, K. H., Rubino, D., & Batterham, R. L. (2021). Once-weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double-blind, placebo-controlled and active-controlled, dose-finding phase 2 trial. Lancet (London, England), 398(10317), 2160–2172. https://doi.org/10.1016/S0140-6736(21)01751-7
• Frias, J. P., Deenadayalan, S., Erichsen, L., Knop, F. K., Lingvay, I., Macura, S., Mathieu, C., Pedersen, S. D., & Davies, M. (2023). Efficacy and safety of co-administered once-weekly cagrilintide 2·4 mg with once-weekly semaglutide 2·4 mg in type 2 diabetes: a multicentre, randomised, double-blind, active-controlled, phase 2 trial. Lancet (London, England), 402(10403), 720–730. https://doi.org/10.1016/S0140-6736(23)01163-7